BioSpace News Archive

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has entered into an agreement to amend certain key terms of its Royalty-Backed Loan agreement (“Royalty-Backed Loan”) with HealthCare Royalty Partners (“HCR”). The key terms amended are summarized as follows:   Revised to provide for rep

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has completed full enrollment of its KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA™ (difelikefalin tablets) for the treatment o

Adamas to acquire global rights to OSMOLEX ER ® for $7.5 million Company to focus on maximizing commercial opportunity for Upnee q™ BRIDGEWATER, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that its subsidiary Osmotica Pharmaceutical US LLC has entered into an agreement to settle its ongoing patent litigation with Adamas Pharmaceuticals, Inc. r

Todos Medical (OTCQB: TOMDF) , an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer’s disease, today announced $3.2 million in sales for the month of November 2020. This represents a 269% increase in monthly sales as compared with October 2020. The majority o

22 scheduled presentations, including 10 oral presentations, examining blood cancers and other key hematology research

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that it will be presenting at the Annual LD Micro Main Event to be held virtually from December 14-15, 2020. Snehal Patel, CEO of Greenwich LifeSciences, will p

First Patient Dosed in Appili Therapeutics’ Phase 3 Clinical Trial of Avigan ® Tablets (Favipiravir) for the Treatment of COVID-19 in the United States Randomized, double-blind, placebo-controlled study expected to enroll more than 800 outpatients with confirmed mild-to-moderate COVID-19 infections Appili’s broad COVID-19 clinical program focuses on the use of oral antivirals as an early intervention against the coronavirus in the outpatient setting

CELEBRATION, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company participated in a late-cycle communication meeting on December 1, 2020, with the U.S. Food and Drug Administration (FDA, or the Agency) regarding the ongoing review of the New Drug Application (NDA) for KP415, KemPharm’s investigational product candidate for the treatment of atten

Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that Keith Dunleavy, M.D., chief executive officer and chairman of the board of Inovalon, and Jonathan R. Boldt, chief financial officer of Inovalon, will participate in a virtual fireside chat at the Guggenheim Digital Health Summit on December 8, 2020 at 9:45 a.m. Eastern Time. Investors may access a live audio webcast

With the recent outbreak of COVID-19, major government authorities across the globe have increased initiatives to contain the spread of the disease.